about
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugCharacterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.In silico modeling and in vivo efficacy of cancer-preventive vaccinations.Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomasAn aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas.Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.Decreased adhesion to endothelial cells and matrix proteins of H-2Kb gene transfected tumour cells.Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma.Molecular and cellular biology of rhabdomyosarcoma.Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.Virus-like particle display of HER2 induces potent anti-cancer responses.Cancer immunoprevention: from mice to early clinical trials.A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma TherapyImmune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasisOX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
P50
Q28538155-36883961-1B1D-4164-B8B4-98A95AA92A16Q33851540-F9C038FA-F393-4746-9BD1-32C2739A37B7Q34141954-6C29DCA3-1331-497A-ACA8-A86FF561686FQ34574879-B9F3A68A-F348-412B-A9AC-28DFAEF591E6Q35067979-2119233B-81A8-42F6-ABF8-58798C699E08Q35103838-5A77878D-2E8F-443F-B747-ADC0EC8BFB2BQ35710332-C63EDB61-1D49-43FF-BD56-C2C7A2BC49C1Q35977896-FB23BFF9-D69C-4094-B344-C026F4363579Q37323073-CF7B2393-7475-4604-A42F-BF264AA29C5FQ37630588-16914122-57F5-4D60-82B4-9C6E3FD6AB60Q37649642-0EF49DBB-F530-4C08-BC1B-86EE9EBC2715Q37691212-11395FFA-917E-43B5-8F8F-C3151D93E6D7Q39642376-8E6B4B1D-E81C-4DAC-BF2E-92283BE40790Q52699878-893FA231-2467-4C87-A200-E2ECCF6C8418Q55472478-86538683-9792-4F71-B1A2-38155F37DC35Q56378218-E4195FA4-5A07-4B9D-8CED-C75B7378B303Q61797742-56D1030D-843E-4E70-B947-DBE79D95675CQ91473857-AA897FE3-55D4-43B7-B713-AD47CDEFE9B8
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lorena Landuzzi
@ast
Lorena Landuzzi
@en
Lorena Landuzzi
@es
Lorena Landuzzi
@nl
type
label
Lorena Landuzzi
@ast
Lorena Landuzzi
@en
Lorena Landuzzi
@es
Lorena Landuzzi
@nl
altLabel
Landuzzi L
@en
prefLabel
Lorena Landuzzi
@ast
Lorena Landuzzi
@en
Lorena Landuzzi
@es
Lorena Landuzzi
@nl
P106
P1153
7004913575
P21
P31
P496
0000-0001-9879-8118